Viatris Unit Gets FDA OK of First Generic of AbbVie's Restasis
February 02 2022 - 2:39PM
Dow Jones News
By Colin Kellaher
The U.S. Food and Drug Administration on Wednesday said it
granted a unit of generic-drug giant Viatris Inc. approval of the
first generic version of AbbVie Inc.'s blockbuster dry-eye drug
Restasis.
The agency said it approved the generic cyclosporine ophthalmic
emulsion 0.05% single-use vials from Mylan Pharmaceuticals Inc. to
increase tear output in patients whose production is presumed to be
suppressed due to ocular inflammation associated with
keratoconjunctivitis sicca, commonly known as dry eye.
AbbVie earlier Wednesday reported 2021 revenue of $1.29 billion
for Restasis, which was part of its roughly $63 billion acquisition
of Allergan in 2020.
Mylan is part of Viatris, the company formed by the 2020 merger
of Pfizer Inc.'s off-patent drugs business Upjohn with generic
drugmaker Mylan NV.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 02, 2022 14:24 ET (19:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
